Positive News Sentiment NASDAQ:TRVI Trevi Therapeutics - TRVI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.46 +0.13 (+5.58%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.30▼$2.6150-Day Range$1.74▼$2.8252-Week Range$0.46▼$4.68Volume45,202 shsAverage Volume42,472 shsMarket Capitalization$147.40 millionP/E RatioN/ADividend YieldN/APrice Target$8.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Trevi Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside235.4% Upside$8.25 Price TargetShort InterestHealthy0.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.90Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.54) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector207th out of 1,055 stocksPharmaceutical Preparations Industry96th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.25, Trevi Therapeutics has a forecasted upside of 235.4% from its current price of $2.46.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.16% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 0.84%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVI. Previous Next 3.8 News and Social Media Coverage News SentimentTrevi Therapeutics has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Trevi Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for TRVI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders39.52% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.51% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to grow in the coming year, from ($0.54) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Trevi Therapeutics (NASDAQ:TRVI) StockTrevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.Read More Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Stock News HeadlinesJanuary 25, 2023 | finance.yahoo.comTrevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day PodcastJanuary 5, 2023 | finance.yahoo.comTrevi Therapeutics Provides Business Update Ahead of Upcoming ConferencesJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 26, 2022 | finance.yahoo.comTrevi Therapeutics, Inc.'s (NASDAQ:TRVI) stock price dropped 13% last week; private equity firms would not be happyDecember 23, 2022 | seekingalpha.comTRVI Trevi Therapeutics, Inc.December 19, 2022 | finance.yahoo.comTrevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care ConferenceNovember 14, 2022 | finance.yahoo.comTrevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical OfficerNovember 13, 2022 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call TranscriptJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 10, 2022 | finance.yahoo.comTrevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business UpdateNovember 9, 2022 | benzinga.comEarnings Outlook For Trevi Therapeutics, Inc. - Common StockNovember 8, 2022 | finance.yahoo.comTrevi Therapeutics to Participate at the Stifel 2022 Healthcare ConferenceNovember 4, 2022 | finance.yahoo.comTrevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022October 27, 2022 | finance.yahoo.comTrevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter MeetingSeptember 23, 2022 | au.investing.comAfter-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on...September 23, 2022 | finance.yahoo.com/C O R R E C T I O N -- Trevi Therapeutics, Inc./September 23, 2022 | finance.yahoo.comTrevi Therapeutics Announces Proposed Public OfferingSeptember 19, 2022 | finance.yahoo.comTrevi Therapeutics Shares Jump After Complete Data From Chronic Cough TrialSeptember 19, 2022 | markets.businessinsider.comTrevi Reports Positive Results From Full Set Of Subjects From CANAL Trial Of HaduvioSeptember 19, 2022 | finance.yahoo.comTrevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary FibrosisSeptember 14, 2022 | finance.yahoo.comIs AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?September 11, 2022 | seekingalpha.comTrevi Therapeutics: Moving ForwardAugust 30, 2022 | finance.yahoo.comTrevi Therapeutics to Host Virtual R&D Day on September 19, 2022August 16, 2022 | nasdaq.comWhat Type Of Shareholders Own The Most Number of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares?August 11, 2022 | finance.yahoo.comTrevi Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdateAugust 8, 2022 | msn.comGloria Trevi On the Highs and Lows of Her 40-Year Career — And What Has Remained Consistent In Her MusicAugust 4, 2022 | finance.yahoo.comTrevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Company Calendar Last Earnings11/10/2022Today1/28/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVI CUSIPN/A CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.25 High Stock Price Forecast$10.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+235.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.00% Return on Assets-46.18% Debt Debt-to-Equity Ratio0.03 Current Ratio8.70 Quick Ratio8.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book3.73Miscellaneous Outstanding Shares59,920,000Free Float36,241,000Market Cap$147.40 million OptionableNot Optionable Beta0.69 Key ExecutivesJennifer L. GoodPresident, Chief Executive Officer & DirectorLisa DelfiniChief Financial OfficerThomas R. SciasciaChief Science OfficerDanine SummersVice President-Medical AffairsDavid J. ClarkChief Medical OfficerKey CompetitorsKronos BioNASDAQ:KRONAesther Healthcare AcquisitionNASDAQ:AEHAAlaunos TherapeuticsNASDAQ:TCRTAnixa BiosciencesNASDAQ:ANIXProPhase LabsNASDAQ:PRPHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,087,437 shares on 11/15/2022Ownership: 3.005%TPG GP A LLCSold 4,073,103 shares on 11/15/2022Ownership: 0.571%Marshall Wace LLPBought 128,324 shares on 11/15/2022Ownership: 0.291%Two Sigma Investments LPBought 79,437 shares on 11/15/2022Ownership: 0.180%State Street CorpBought 37,200 shares on 11/15/2022Ownership: 0.175%View All Insider TransactionsView All Institutional Transactions TRVI Stock - Frequently Asked Questions Should I buy or sell Trevi Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares. View TRVI analyst ratings or view top-rated stocks. What is Trevi Therapeutics' stock price forecast for 2023? 4 analysts have issued 1 year target prices for Trevi Therapeutics' shares. Their TRVI share price forecasts range from $6.00 to $10.00. On average, they predict the company's stock price to reach $8.25 in the next year. This suggests a possible upside of 235.4% from the stock's current price. View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts. How have TRVI shares performed in 2023? Trevi Therapeutics' stock was trading at $1.93 at the beginning of the year. Since then, TRVI stock has increased by 27.5% and is now trading at $2.46. View the best growth stocks for 2023 here. When is Trevi Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our TRVI earnings forecast. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings data on Thursday, November, 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX). When did Trevi Therapeutics IPO? (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. What is Trevi Therapeutics' stock symbol? Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI." How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Trevi Therapeutics' stock price today? One share of TRVI stock can currently be purchased for approximately $2.46. How much money does Trevi Therapeutics make? Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $147.41 million. The company earns $-33,940,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. How can I contact Trevi Therapeutics? Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com. This page (NASDAQ:TRVI) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.